TR200101245T2 - N-arilsulfonil-aminoasit-omega-amidler - Google Patents

N-arilsulfonil-aminoasit-omega-amidler

Info

Publication number
TR200101245T2
TR200101245T2 TR2001/01245T TR200101245T TR200101245T2 TR 200101245 T2 TR200101245 T2 TR 200101245T2 TR 2001/01245 T TR2001/01245 T TR 2001/01245T TR 200101245 T TR200101245 T TR 200101245T TR 200101245 T2 TR200101245 T2 TR 200101245T2
Authority
TR
Turkey
Prior art keywords
arylsulfonyl
omega
amides
amino
formula
Prior art date
Application number
TR2001/01245T
Other languages
English (en)
Inventor
Schwab Wilfried
Thorwart Werner
Schudok Manfred
Haase Burkhard
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200101245T2 publication Critical patent/TR200101245T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Abstract

Formül I bilesikleri ve/veya formül I bilesiginin bir stereoizomer hali ve/veya formül I bilesiginin fizyolojik olarak tolere edilebilir tuzu, matris parçalayici metaloproteinazlarin etkili oldugu hastaliklarin tedavisine ve hastaliklarin önlenmesine yönelik tibbi ilaçlarin üretimine uygunluk göstermektedirler.
TR2001/01245T 1998-11-06 1999-10-21 N-arilsulfonil-aminoasit-omega-amidler TR200101245T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19851184A DE19851184A1 (de) 1998-11-06 1998-11-06 N-Arylsulfonyl-aminosäure-omega-amide

Publications (1)

Publication Number Publication Date
TR200101245T2 true TR200101245T2 (tr) 2001-10-22

Family

ID=7886902

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01245T TR200101245T2 (tr) 1998-11-06 1999-10-21 N-arilsulfonil-aminoasit-omega-amidler

Country Status (23)

Country Link
US (2) US6201130B1 (tr)
EP (1) EP1124797B1 (tr)
JP (1) JP4348014B2 (tr)
KR (1) KR100655632B1 (tr)
CN (1) CN1206213C (tr)
AR (1) AR021086A1 (tr)
AT (1) ATE260889T1 (tr)
AU (1) AU757602B2 (tr)
BR (1) BR9915729A (tr)
CA (1) CA2350031C (tr)
CZ (1) CZ302291B6 (tr)
DE (2) DE19851184A1 (tr)
DK (1) DK1124797T3 (tr)
ES (1) ES2213405T3 (tr)
HK (1) HK1041686B (tr)
HU (1) HUP0104122A3 (tr)
ID (1) ID28810A (tr)
PL (1) PL198827B1 (tr)
PT (1) PT1124797E (tr)
RU (1) RU2228330C2 (tr)
TR (1) TR200101245T2 (tr)
WO (1) WO2000027808A1 (tr)
ZA (1) ZA200103485B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
MXPA05010165A (es) * 2003-04-15 2005-11-16 Warner Lambert Co Derivados de prolina biciclicos [c]-condensados y su uso para el tratamiento de estados artriticos.
CA2525437C (en) * 2003-05-12 2009-04-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
BRPI0512651A (pt) * 2004-06-29 2008-03-25 Pfizer Prod Inc método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis
MXPA06014022A (es) * 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
AU2006268183B2 (en) 2005-07-11 2012-08-09 Wyeth Glutamate aggrecanase inhibitors
CA2624866A1 (en) 2005-10-13 2007-04-19 Wyeth Methods for preparing glutamic acid derivatives
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2953932B1 (en) * 2013-02-06 2017-03-01 Merck Patent GmbH Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1063026A1 (ru) * 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью
JP2764262B2 (ja) 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (tr) 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB2303850B (en) 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP2000500161A (ja) * 1995-06-28 2000-01-11 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー フッ素重合体のナノ複合体
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren

Also Published As

Publication number Publication date
CZ20011506A3 (cs) 2001-08-15
KR20010080385A (ko) 2001-08-22
PL198827B1 (pl) 2008-07-31
ATE260889T1 (de) 2004-03-15
AR021086A1 (es) 2002-06-12
PL347574A1 (en) 2002-04-08
HUP0104122A2 (hu) 2002-03-28
KR100655632B1 (ko) 2006-12-12
CN1206213C (zh) 2005-06-15
ID28810A (id) 2001-07-05
RU2228330C2 (ru) 2004-05-10
AU1153000A (en) 2000-05-29
CA2350031A1 (en) 2000-05-18
JP4348014B2 (ja) 2009-10-21
EP1124797B1 (de) 2004-03-03
US6335333B1 (en) 2002-01-01
HK1041686B (zh) 2005-09-23
US6201130B1 (en) 2001-03-13
WO2000027808A1 (de) 2000-05-18
CA2350031C (en) 2010-01-26
BR9915729A (pt) 2001-10-23
DK1124797T3 (da) 2004-07-05
JP2002529447A (ja) 2002-09-10
HK1041686A1 (en) 2002-07-19
ZA200103485B (en) 2001-12-04
DE59908769D1 (de) 2004-04-08
PT1124797E (pt) 2004-07-30
ES2213405T3 (es) 2004-08-16
CZ302291B6 (cs) 2011-02-09
AU757602B2 (en) 2003-02-27
DE19851184A1 (de) 2000-05-11
HUP0104122A3 (en) 2002-04-29
CN1332724A (zh) 2002-01-23
EP1124797A1 (de) 2001-08-22

Similar Documents

Publication Publication Date Title
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TR200101120T2 (tr) Serin proteaz inhibitörü
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
BR0109703A (pt) Derivados de piperazina
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
GB9907571D0 (en) Compounds
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
SE0100684D0 (sv) New subject-matter
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
SE0004827D0 (sv) Therapeutic compounds
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos